<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196414</url>
  </required_header>
  <id_info>
    <org_study_id>myeloma-01</org_study_id>
    <nct_id>NCT03196414</nct_id>
  </id_info>
  <brief_title>Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma</brief_title>
  <official_title>Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placing a tumor antigen chimeric receptor that has been created in the laboratory into&#xD;
      patient autologous or donor-derived T cells may make the body build immune response to kill&#xD;
      cancer cells. Genetically engineered lymphocyte (CART) therapy has showed good safety and&#xD;
      efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see&#xD;
      if this helps people with multiple myeloma.To test the safety and efficacy of giving&#xD;
      targeting CD138 or B-cell maturation antigen or CD19 or more antigens T cells in treating&#xD;
      patients with multiple myeloma that is refractory to further chemotherapy or relapsed(after&#xD;
      stem cell transplantation or intensive chemotherapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults ages 18-75 with Relapsed and/or Chemotherapy Refractory Multiple Myelomas.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants may be screened with:&#xD;
&#xD;
      Medical history Physical exam Blood and urine tests Heart tests Bone marrow sample Multiple&#xD;
      scans and X-rays Lymphocytes are collected by apheresis from the enrolled patient or a&#xD;
      healthy donor. Blood is removed through a needle in an arm. The rest of the blood is returned&#xD;
      through a needle in the other arm.&#xD;
&#xD;
      The cells will be changed in a laboratory. Participants will get 2 chemotherapy drugs over 5&#xD;
      days. Two days later, participants will get an intravenous (IV) catheter in an arm. They will&#xD;
      get the split doses CART cells on day0, day1, day2 through the IV in 1 infusion.&#xD;
&#xD;
      After this, participants will stay in the hospital for at least 9 days and stay nearby for 2&#xD;
      weeks. Then they will have blood tests and see a doctor.&#xD;
&#xD;
      Participants will visit the clinic at 1, 2, 3, 6, 9 and 12 months after the infusion, then&#xD;
      every 6 months until two years after infusion. A bone marrow sample will be taken at the&#xD;
      3-month visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if there is grade 3 to 5 cytokine release syndrome</measure>
    <time_frame>2 weeks-12 months after initial dose</time_frame>
    <description>Number of Patients With Grade 3 Through Grade 5 Cytokine Release Syndrome(CRS) That Are Related to Study Intervening Measures, Graded According to NCI CTCAE Version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigators try to assess major reaction rate (MRR, PR+VGPR+CR) at the end of the research.</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Number of Patients achieved major reaction rate (MRR;PR+VGPR+CR) According to IMWG response criteria at the end of the research.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Investigators try to test CART 138 cells copies in vivo.</measure>
    <time_frame>2 years</time_frame>
    <description>CART Cell survival time by testing CART-138/BCMA cells copies in vivo through PCR Method.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CART-138/BCMA/19/more</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART-138/BCMA/19/more</intervention_name>
    <description>Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight</description>
    <arm_group_label>CART-138/BCMA/19/more</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CD138 or BCMA antigen positive multiple myeloma in patients with no available curative&#xD;
             treatment options (such as autologous or allogeneic SCT).&#xD;
&#xD;
          -  Relapsed and/or refractory multiple myeloma.&#xD;
&#xD;
          -  Relapsed after prior autologous or allogenic SCT.&#xD;
&#xD;
          -  Expected survival ≥ 3 months&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Blood coagulation function: PT and APTT &lt; 2x normal&#xD;
&#xD;
          -  Arterial blood oxygen saturation &gt; 92%&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) &lt; 3x normal&#xD;
&#xD;
          -  Karnofsky scores ≥ 60 and ECOG score ≤ 2&#xD;
&#xD;
          -  Adequate venous access for apheresis, and no other contraindications for leukapheresis&#xD;
&#xD;
          -  Patients should not take system chemotherapy in one month and immunotherapy in three&#xD;
             months prior to CART cells infusion.&#xD;
&#xD;
          -  Voluntary informed consent is given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Previously treatment with any gene therapy products&#xD;
&#xD;
          -  Any uncontrolled active medical disorder that would preclude participation as&#xD;
             outlined.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  History of myocardial infarction and severe arrhythmia in half a year&#xD;
&#xD;
          -  Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency&#xD;
             Disease).&#xD;
&#xD;
          -  Patients with fever of unknown origin (T &gt; 38℃)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu cheng cheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital,Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling zhi Yan, PhD</last_name>
    <phone>13584821140</phone>
    <email>yanlingzhi@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital, Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling zhi Yan, Phd</last_name>
      <phone>13584821140</phone>
      <email>yanlingzhi@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

